In vivo efficacy of BKI-1708 was previously demonstrated [29] in an IFNγ-KO immunocompromised acute mouse model of Cryptosporidium infection with 5 days of once daily (QD) oral doses as low as 8 mg/kg. This evidence concerns the gene IFNG and cryptosporidiosis.